Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab

    Research output: Contribution to journalLetterResearchpeer-review

  1. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Early prevention of diabetic nephropathy is not successful as early interventions have shown conflicting results, partly because of a lack of early and precise indicators of disease development. Urinary proteomics has shown promise in this regard and could identify those at high risk who might benefit from treatment. In this study we investigate its utility in a large type 2 diabetic cohort with normoalbuminuria.

METHODS: We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial. Patients were allocated to candesartan or placebo, with the aim of slowing the progression of retinopathy. The secondary endpoint was development of persistent microalbuminuria (three of four samples). We used a previously defined chronic kidney disease risk score based on proteomic measurement of 273 urinary peptides (CKD273-classifier). A Cox regression model for the progression of albuminuria was developed and evaluated with integrated discrimination improvement (IDI), continuous net reclassification index (cNRI) and receiver operating characteristic curve statistics.

RESULTS: Seven hundred and thirty-seven patients were analysed and 89 developed persistent microalbuminuria (12%) with a mean follow-up of 4.1 years. At baseline the CKD273-classifier predicted development of microalbuminuria during follow-up, independent of treatment (candesartan/placebo), age, gender, systolic blood pressure, urine albumin excretion rate, estimated glomerular filtration rate, HbA1c and diabetes duration, with hazard ratio 2.5 [95% confidence interval (CI) 1.4-4.3; P = 0.002] and area under the curve 0.79 (95% CI 0.75-0.84; P < 0.0001). The CKD273-classifier improved the risk prediction (relative IDI 14%, P = 0.002; cNRI 0.10, P = 0.043).

CONCLUSIONS: In this cohort of patients with type 2 diabetes and normoalbuminuria from a large intervention study, the CKD273-classifier was an independent predictor of microalbuminuria. This may help identify high-risk normoalbuminuric patients for preventive strategies for diabetic nephropathy.

Original languageEnglish
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Volume32
Issue number11
Pages (from-to)1866-1873
Number of pages7
ISSN0931-0509
DOIs
Publication statusPublished - Nov 2017

ID: 49713590